Silexion Therapeutics Corp. will attend the 7th RNAi-Based Therapeutics Summit in Boston, MA, from January 27-29. The company is developing SIL204, a next-generation siRNA therapy to silence mutated KRAS oncogenes, common in human cancers. SIL204 is set to enter a Phase 2/3 clinical study for locally advanced pancreatic cancer in mid-2026. Silexion management will host one-on-one meetings during the summit and is an official partner of the event. The company aims to innovate treatments for solid tumor cancers with mutated KRAS, pushing boundaries in oncology. For more information, visit their website.

Read more at GlobeNewswire: Silexion Therapeutics to Attend 7th Annual RNAi-Based